Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
AvalereJuly 11, 2025

GLP-1 Coverage for Obesity Treatment Remains Limited in Medicaid Despite Growing Pipeline

Coverage of anti-obesity medications, particularly GLP-1 receptor agonists, varies significantly across payer types, with Medicaid programs showing particularly restrictive policies despite a growing pipeline of over 40 products and projected market growth to $150 billion by 2030. The analysis examines how differences between commercial, Medicare, and Medicaid coverage create access disparities, with implications for state Medicaid programs navigating budget pressures alongside federal policy efforts to expand access. Medicaid managed care plans face particular challenges balancing long-term value against immediate cost concerns as member uptake increases.

Pharmacy · Managed Care

Read the full analysis at Avalere →

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Avalere

← Analysis & Perspectives

Get the daily briefing.